A biological solution to the Iranian threat

“I have the solution in my pocket,” said Yanay, CEO and president of Pluristem Therapeutics.

By
May 8, 2017 00:02
1 minute read.
PARTICIPANTS IN THE conference economic panel (from left): Yaky Yanay, CEO & president of Pluristem

PARTICIPANTS IN THE conference economic panel (from left): Yaky Yanay, CEO & president of Pluristem Therapeutics; Prof. Isaac Ben-Israel, member of EMET Prize Award Committee; Bini Zomer, Israel country manager, Noble Energy; moderator Dr. Efraim Chalamish; Nissim Zioni ,founder & CEO of Pitchon-Lev. (photo credit: SIVAN FARAG)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Sitting on stage at The Jerusalem Post Annual Conference in New York on Sunday, innovator Yaky Yanay pulled a small glass vial out of his pocket – promising a solution to Iranian nuclear threats.

“I have the solution in my pocket,” said Yanay, CEO and president of Pluristem Therapeutics.

Be the first to know - Join our Facebook page.


The Haifa-based company, which aims to create “the next generation of biological therapeutic products,” specializes in harnessing placental cells to treat a variety of diseases using a three-dimensional platform. For one such ailment that Pluristem is targeting, Acute Radiation Syndrome, the company is currently conducting dose evaluation studies with the US National Institutes of Health’s NIAID PLX-R18 cells – the same cells in Yanay’s glass vial.

“If we can inject these cells after exposure to radiation, we will be able to keep the entire population alive,” he said.

As Pluristem continues to delve into cell therapy research, the company is focusing on increasing longevity in the face of illnesses that today have no viable treatments. In addition, the company expressed hopes that the introduction of cell therapies could cut government healthcare costs significantly while improving care – offering accessible, safe and effective treatments.

“The world is aging dramatically,” Yanay said. “We’ve doubled life expectancy in past 150 years and we need new technologies.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Ben Cardin, United States Senator (D) from Maryland, interviewed by The Jerusalem Post's Lahav Harko
April 29, 2018
Reporter's Notebook: Effusive celebration of Israel in NY

By LAHAV HARKOV